Tara Hrobowski-Blackman, MD
Advanced Heart Failure and Transplant Cardiology · Largo, FLNPI 1699931915
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,800 of the $101,830 with a category attached, or 76.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 66.1% of it on its own, with 24 other manufacturers making up the rest.
Across 310 payments — averaging $328.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$67K
- Abiomed$13K
- Pfizer$9K
- Actelion Pharmaceuticals US, Inc.$4K
- Abbott$3K
- Ancora Heart, Inc.$3K
- plus $2K from 19 others
What the payments were for
- Consulting fees$2,1002%
- Speaking & faculty fees$77,80076%
- Travel & lodging$11,22611%
- Food & beverage$10,49710%
- Education$2070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 101 | $67,341 |
| Abiomed | 44 | $13,350 |
| Pfizer | 9 | $9,236 |
| Actelion Pharmaceuticals US, Inc. | 22 | $3,859 |
| Abbott | 75 | $3,041 |
| Ancora Heart, Inc. | 10 | $2,773 |
| Getinge USA Sales, LLC | 2 | $417 |
| Cvrx, Inc. | 6 | $368 |
| Itamar Medical Inc | 1 | $216 |
| Boston Scientific | 3 | $208 |
| E.r. Squibb & Sons, L.L.C. | 6 | $159 |
| Medtronic | 3 | $143 |
| Novartis | 6 | $115 |
| Impulse Dynamics (USA) Inc. | 1 | $95 |
| Merck | 3 | $87 |
| AstraZeneca | 4 | $64 |
| Bridgebio Pharma, Inc. | 2 | $64 |
| Philips North America LLC | 1 | $46 |
| Johnson & Johnson | 2 | $45 |
| Boehringer Ingelheim | 2 | $42 |
| Akcea Therapeutics, Inc. | 2 | $42 |
| Bayer | 2 | $35 |
| W. L. Gore & Associates, Inc. | 1 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Kestra Medical Technology Services, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$65,282
- Impella$11,274
- VYNDAQEL$9,000
- UPTRAVI$3,182
- OPSUMIT$3,182
- AccuCinch$2,710
- CARDIOMEMS$412
- Vasoview Hemopro 2$399
- CardioMEMS HF System$352
- Barostim Neo System$272
- WatchPat$216
- WATCHMAN Access System$170
- Mitra Clip system$158
- HeartMate$152
- HeartMate 3 Left Ventricular Assist Device$118
- CoreValve Evolut$111
- CAMZYOS$105
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$103
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$100
How this compares
$101,830 in reported general payments places this provider in the 80th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 11 | $228,041 |
| OpsumitMacitentan | 17 | $217,426 |
| EntrestoSacubitril/Valsartan | 134 | $135,058 |
| EliquisApixaban | 72 | $56,866 |
| FarxigaDapagliflozin Propanediol | 63 | $53,694 |
| JardianceEmpagliflozin | 38 | $28,233 |
| Tacrolimus | 77 | $9,708 |
| Valganciclovir Hcl | 15 | $4,749 |
| Mycophenolate Mofetil | 43 | $4,492 |
| Sildenafil Citrate | 37 | $4,081 |
| Isosorbide Dinitrate | 12 | $1,753 |
| Potassium Chloride | 84 | $1,571 |
| Clonidine | 17 | $1,389 |
| Hydralazine Hcl | 65 | $1,139 |
| Metoprolol Succinate | 78 | $633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $3,859 | $445,46628 claims |
| NovartisEntresto | $115 | $135,058134 claims |
| PfizerEliquis | $9,236 | $56,86672 claims |
| AstraZenecaFarxiga | $64 | $53,69463 claims |
| Boehringer IngelheimJardiance | $42 | $28,23338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Largo
- Kelly McCantsWinter Park$445K
- Naveen BellamOrlando$414K
- Phillip HabibDelray Beach$305K
- Waqas GhummanAtlantis$276K
- David SnipeliskyWeston$250K
- Elsy NavasNaples$234K
- David BaranWeston$116K
- Rohan GoswamiJacksonville$112K
- Stacy MandrasOrlando$100K
- Omar Wever-PinzonMiami$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.